Details werden geladen...
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma | The Manila Times
Approval Offers New Hope for Patients with Anti-PD-1 Refractory Melanoma
Ähnliche Seiten
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | The Manila Times
https://www.manilatimes.net/2026/06/04/tmt-newswire/globenewswire/iovances-amtagvi-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-australia/2358282
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease | The Manila Times
https://www.manilatimes.net/2026/07/02/tmt-newswire/globenewswire/fda-approves-first-gene-therapy-for-young-children-with-sickle-cell-disease/2377168Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma | The Manila Times
https://www.manilatimes.net/2026/05/31/tmt-newswire/globenewswire/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma/2355202
New treatment offers hope for endometrial cancer patients
https://nypost.com/2026/05/20/health/new-treatment-offers-hope-for-endometrial-cancer-patients/Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer | The Manila Times
https://www.manilatimes.net/2026/07/15/tmt-newswire/globenewswire/celcuity-announces-fda-approval-of-revtorpyk-gedatolisib-for-the-treatment-of-hrher2-pik3ca-wild-type-locally-advanced-or-metastatic-breast-cancer/2384591